Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Natera, Inc. - Common Stock (NQ:NTRA)

169.34 +1.09 (+0.65%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Natera, Inc. - Common Stock

< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
Benzinga's Top Ratings Upgrades, Downgrades For March 8, 2022
Upgrades According to Janney Montgomery Scott, the prior rating for Wintrust Financial Corp (NASDAQ:WTFC) was changed from Neutral to Buy. Wintrust Finl earned $1.58 in the fourth... 
Via Benzinga
Natera: Q4 Earnings Insights
Natera (NASDAQ:NTRA) reported its Q4 earnings results on Thursday, February 24, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Natera... 
Via Benzinga
Natera's Debt Overview
Over the past three months, shares of Natera (NASDAQ:NTRA) decreased by 34.50%. Before we understand the importance of debt, let us look at how much debt Natera has. Check... 
Via Benzinga
The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (... 
Via Benzinga
NASDAQ:NTRA Investor Alert: Investigation over Possible Securities Laws Violations by Natera, Inc.
San Diego, CA -- (SBWIRE) -- 01/28/2022 -- Natera, Inc are under investigation over potential securities laws violations in connection with certain financial statements. 
Via SBWire
INVESTOR ALERT: Kirby McInerney LLP Continues Investigation of Shareholder Claims on Behalf of Natera, Inc. (NTRA) Investors
From Kirby McInerney LLP
Via Business Wire
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front... 
Via Benzinga
Investigation Notice: The Schall Law Firm Encourages Investors in Natera, Inc. with Losses of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Investigation Alert: The Schall Law Firm Encourages Investors in Natera, Inc. with Losses of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Regulatory Compliance
Ongoing Investigation Reminder: The Schall Law Firm Encourages Investors in Natera, Inc. with Losses of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Investigation Notice: The Schall Law Firm Encourages Investors in Natera, Inc. with Losses of $100,000 to Contact the Firm
Los Angeles - (NewMediaWire) - January 19, 2022 - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Natera, Inc.... 
Via NewMediaWire
INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Natera, Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
Landmark SMART Study Demonstrates High Accuracy of Natera’s Panorama® NIPT for 22q11.2 Deletion Screening
From Natera
Via Business Wire
SHAREHOLDER ALERT: Robbins LLP Investigates Natera, Inc. (NTRA) on Behalf of Shareholders
From Robbins LLP
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Natera, Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
ROSEN, A LEADING LAW FIRM, Encourages Natera, Inc. Investors with Losses to Inquire About Class Action Investigation – NTRA
From Rosen Law Firm
Via Business Wire
FeganScott Announces Investigation into Prenatal Testing Options Revealing Flawed Genetic Results
--News Direct-- 
Via News Direct
INVESTOR ALERT: Kirby McInerney LLP Continues Investigation of Shareholder Claims on Behalf of Natera, Inc. (NTRA) Investors
From Kirby McInerney LLP
Via Business Wire
SHAREHOLDER ALERT: Robbins LLP Investigates Natera, Inc. (NTRA) on Behalf of Shareholders
From Robbins LLP
Via Business Wire
Stocks That Hit 52-Week Lows On Friday
Before 10 am on Friday, 110 companies set new 52-week lows. Interesting Points From Today's 52-Week Lows: Humana (NYSE:HUM) was the biggest company on a market cap... 
Via Benzinga
Natera Announces Expansion Into Early Cancer Detection and Screening
From Natera, Inc.
Via Business Wire
NATERA ALERT: Bragar Eagel & Squire, P.C. is Investigating Natera, Inc. on Behalf of Natera Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Natera, Inc. (NTRA) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Natera, Inc. (NTRA) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Natera, Inc. (NTRA) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
7 Stocks to Buy in November in Light of Their October Dip
October was a good month in the markets. It won't be easy to find stocks to buy on the dip. However, here are seven that will do the trick. 
Via InvestorPlace
Medicare Coverage For Natera's Signatera For Pan-Cancer Immunotherapy Monitoring
CMS Molecular Diagnostics Services Program (MolDX) has issued a final local coverage determination (LCD) for pan-cancer immunotherapy monitoring using Natera Inc... 
Via Benzinga
Natera Raises FY21 Sales Outlook After Mixed Q3 earnings
Natera Inc (NASDAQ: NTRA) posted Q3 sales of $158.1 million, +61% Y/Y, beating the consensus of $151.36 million, driven by an increase in test volume and product... 
Via Benzinga
Natera Inc (NTRA) Q3 2021 Earnings Call Transcript
NTRA earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &... 
Via Benzinga
< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.